These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 327909

  • 1. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
    Lalos O, Frankendal B, Rudolphi O.
    Ann Chir Gynaecol; 1977; 66(3):131-134. PubMed ID: 327909
    [Abstract] [Full Text] [Related]

  • 2. Fibrin degradation products and the diagnosis of ovarian carcinoma.
    Anstey JT, Blythe JG.
    Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Determination of fibrinogen-fibrin degradation factors in neoplasms].
    Petrella V, Massara G, Parachini F, Silvera F, Cantone R.
    Minerva Med; 1988 Feb; 79(2):117-21. PubMed ID: 3352945
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Unreliability of current serum fibrin degradation product (FDP) assays.
    Gaffney PJ, Perry MJ.
    Thromb Haemost; 1985 Jun 24; 53(3):301-2. PubMed ID: 3901388
    [Abstract] [Full Text] [Related]

  • 11. [Fibrin fibrinogen degradation products in the urine and blood in patients with diabetes mellitus and renal complications].
    Astrug A, Shipkova P.
    Vutr Boles; 1982 Jun 24; 21(5):81-8. PubMed ID: 7164412
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N, Kagiya H, Kumagai T, Kameko M, Tozuka M, Saito H, Katsuyama T, Kanai M.
    Rinsho Byori; 1990 Feb 24; 38(2):201-7. PubMed ID: 2329722
    [Abstract] [Full Text] [Related]

  • 13. Release of fibrinolytic activators from human ovarian tumours in organ culture.
    Svanberg L, Astedt B.
    Ann Chir Gynaecol; 1976 Feb 24; 65(6):405-7. PubMed ID: 1020906
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer.
    Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Weiss C, Genazzani AR.
    Gynecol Oncol; 1997 Jul 24; 66(1):85-8. PubMed ID: 9234926
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Persistent discrepancy between FDP and D-dimer in a patient with acute leukemia].
    Sato N, Takahashi H, Nikuni K, Seki Y, Wada K, Tatewaki W, Shibata A.
    Rinsho Ketsueki; 1995 Mar 24; 36(3):212-7. PubMed ID: 7783324
    [Abstract] [Full Text] [Related]

  • 20. A rapid turbidimetric determination of fibrinogen degradation products (FDP).
    Verbruggen HW, Wessels JM.
    Thromb Haemost; 1978 Feb 28; 39(1):12-21. PubMed ID: 580487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.